Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Common Equity (2018 - 2019)

DiaMedica Therapeutics' Common Equity history spans 2 years, with the latest figure at $9.7 million for Q3 2019.

  • For Q3 2019, Common Equity rose 136.01% year-over-year to $9.7 million; the TTM value through Sep 2019 reached $9.7 million, up 136.01%, while the annual FY2018 figure was $17.0 million, N/A changed from the prior year.
  • Common Equity reached $9.7 million in Q3 2019 per DMAC's latest filing, down from $11.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $48.0 million in Q2 2018 to a low of $4.1 million in Q3 2018.